Stockreport

Aytu BioPharma FQ4 2025 Earnings Preview [Seeking Alpha]

Aytu BioPharma, Inc.  (AYTU) 
NASDAQ:AMEX Investor Relations: aytubio.com/investors/stock-information
PDF The consensus EPS Estimate is -$0.06 and the consensus Revenue Estimate is $17.92M. More on Aytu BioPharma FDA targets drug marketing, advertising with slew of warn [Read more]